Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

BioXplor’s AI/Cognitive Software Platform accelerates and greatly reduces the cost of discovery research and clinical trials, with a primary focus on rare and inflammatory diseases data.

Project description

A pioneering 'discovery support' platform mines words and data to identify critical links

Scientific discovery is rarely the result of a serendipitous light bulb, and more a result of analyses of tremendous amounts of literature and data in interdisciplinary fields. BIOXPLOR is slashing the time and cost of discovery research and clinical trials and significantly augmenting success with its virtual experimental AI platform. It combines natural language processing and machine learning to accelerate data interpretation from unstructured literature (millions of full-text papers, clinical trials and more) and structured data (such as proprietary databases). A few of the myriad tasks the platform accomplishes include generating hypotheses and ranking their likelihood of success, investigating interrelationships among diseases, genetics and drugs, predicting novel indications for existing drugs, and adverse events for novel indications.

Objective

BioXplor’s AI/Cognitive Software Platform accelerates and greatly reduces the cost of discovery research and clinical trials, with a primary focus on rare and inflammatory diseases data. The technology has shown a 5-25x reduction in time and 70% cost savings in pilots so far. (TLR stage 6 &7 tests in 5x Biotech and Pharma companies).
BioXplor has achieved the Seal of Excellence for our Phase I application in March 2019 (score 13.5) and November 2018 (score 13.09) submissions. Last year, we have been completed acceleration programs at UC Berkeley’s SkyDeck and at Merck, and since then significant progress in building the platform to TLR stage 7 and acquiring new customers and revenue. The platform has been successfully used in tests with 5x Pharma and biotech companies (Merck, Bayer, Novartis, Abcam, EdemedX), and we have 5 new leads, for our platform for Discovery applications (antibodies, recombinant proteins, biomarker discovery, immunoassays, drug target ID) and Clinical applications (indication expansion, super-responder ID for drug-repositioning, and patient stratification for Biosimilars, all in inflammation projects with Biotech and Pharma). The current submission is aimed towards bringing BioXplor’s Platform to TLR stage 8, and deploying the our fully tested solution in operational environments at Pharma, Biotech and Academic Research Institutes, for which we are already negotiating pre-orders including 3 year multiyear contracts and 5-10 year partnerships. We have since partnered UC Berkeley, gained access to clinical trials patient data from a major pharma, become a discovery forum member with the 100K Genomes Project, and been selected as a consortium partner for an EU project in the oncology space. We have built a pipeline of EUR750k, with 2019 revenues projected at EUR500k and project revenues of $2M by 2021. We have been requested to deliver the solution to manage 15-20 clinical trials (secondary use of data) for a Top 2 Pharma company

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

SME-1 - SME instrument phase 1

See all projects funded under this funding scheme

Call for proposal

(opens in new window) H2020-EIC-SMEInst-2018-2020

See all projects funded under this call

Coordinator

BIOXPLOR LIMITED
Net EU contribution
€ 50 000,00
Address
9C THE BOTTLEWORKS
Dublin 4 Dublin
Ireland
SME
Yes
Region
Ireland Eastern and Midland Dublin
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 71 429,00